<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
<channel>


<title>aktiencheck.de - Forum - MEDWELL CAPITAL CORP.</title>
<link>http://www.aktiencheck.de</link>
<description>aktiencheck.de</description>
<language></language>
<copyright>aktiencheck.de</copyright>
<lastBuildDate>Mon, 27 Apr 2026 18:13:28 +0200</lastBuildDate>
<ttl>2</ttl>








<item>
<title>Schnelle 50 % Chance nach Panikverkauf !</title>
<link>http://www.aktiencheck.de/forum/Schnelle_50_Chance_nach_Panikverkauf-A1C09Q-t382553</link>
<guid>http://www.aktiencheck.de/forum/Schnelle_50_Chance_nach_Panikverkauf-A1C09Q-t382553</guid>
<description>der Freiherr hat mir geschrieben,, Münchhausen bespricht niemals Aktien, die nach seiner Posaunerei wieder - mangels Substanz - abstürzen.
Für bioms hatte er gewaltig getrommelt. Jetzt nichts mehr.
Da 90 % Verlust für seine Aktien keine Seltenheit sind, könnte bio weiter abstürzen.
Aber letztlich behält er doch immer Recht. Also, kaufen, kaufen, kaufen. [&lt;a href=&#034;http://www.aktiencheck.de/forum/Schnelle_50_Chance_nach_Panikverkauf-A1C09Q-t382553&#034;&gt;mehr&lt;/a&gt;]</description>
</item>







<item>
<title>MS-Medikament in Phase III...</title>
<link>http://www.aktiencheck.de/forum/MS_Medikament_in_Phase_III-A1C09Q-t280677</link>
<guid>http://www.aktiencheck.de/forum/MS_Medikament_in_Phase_III-A1C09Q-t280677</guid>
<description>BioMs Q2 results, BioMS Medical announces second quarter 2009 results
Press Release 
Source: BioMS Medical Corp. 
On Friday July 17, 2009, 5:00 pm EDT 
       Buzz up! 0 Print
 
Toronto Stock Exchange Symbol: MS
EDMONTON, July 17 /CNW/ - BioMS Medical Corp. (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009.

"The pivotal phase III MAESTRO-01 trial has completed the last patient last visit, and we are expecting results from this study within the second half of this year. This is the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, our drug could represent a valuable new treatment for MS patients," said Kevin Giese, President and CEO of BioMS Medical.

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotid [&lt;a href=&#034;http://www.aktiencheck.de/forum/MS_Medikament_in_Phase_III-A1C09Q-t280677&#034;&gt;mehr&lt;/a&gt;]</description>
</item>

</channel>
</rss>







